Safety and Efficacy Evaluation Of Pregabalin (Lyrica) With Patients With Generalized Anxiety Disorder

Phase 4 Completed 615 enrolled Viatris Inc.

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to characterize the safety and efficacy in patients with generalized anxiety disorder after short- (3 months) and long-term (6 months) use of Pregabalin (Lyrica).

Timeline

Start: 2009-05
Primary completion: 2012-04
Completion: 2012-04

Publications

Kasper S, Iglesias-Garcia C, Schweizer E, Wilson J, DuBrava S, Prieto R, Pitman VW, Knapp L. Pregabalin long-term treatment and assessment of discontinuation in patients with generalized anxiety disorder. Int J Neuropsychopharmacol. 2014 May;17(5):685-95. doi: 10.1017/S1461145713001557. Epub 2013 Dec 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Lorazepam	Small molecule	3 mg	—
Comparator	Lorazepam	Small molecule	4 mg	—
Subject	Pregabalin	Small molecule	150 mg	—
Subject	Pregabalin	Small molecule	300 mg	—
Subject	Pregabalin	Small molecule	450 mg	—
Subject	Pregabalin	Small molecule	600 mg	—

Safety and Efficacy Evaluation Of Pregabalin (Lyrica) With Patients With Generalized Anxiety Disorder

Summary

Timeline

Publications

Drugs

Indications